Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Evandro de Azambuja

Showing results (101-110 of 259) with videos related to

Pageof 26
Sort By:
Expert Opinion on Investigational Drugs|March 4, 2022
Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancerElisa Agostinetto, Agnese Losurdo, Guilherme Nader-Marta, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 16, 2017
Role of Troponins I and T and N-Terminal Prohormone of Brain Natriuretic Peptide in Monitoring Cardiac Safety of Patients With Early-Stage Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Receiving Trastuzumab: A Herceptin Adjuvant Study Cardiac Marker SubstudyDimitrios Zardavas, Thomas M Suter, Dirk J Van Veldhuisen, et al.
European Journal of Cancer (Oxford, England : 1990)|March 19, 2021
Cardiotoxicity of immune checkpoint inhibitors: A systematic review and meta-analysis of randomised clinical trialsElisa Agostinetto, Daniel Eiger, Matteo Lambertini, et al.
The Oncologist|June 15, 2022
Ovarian Function Suppression: A Deeper Consideration of the Role in Early Breast Cancer and its Potential Impact on Patient Outcomes: A Consensus Statement from an International Expert PanelBolivar Arboleda, Rupert Bartsch, Evandro de Azambuja, et al.
Expert Review of Anticancer Therapy|June 24, 2024
Current practices in oncofertility counseling: updated evidence on fertility preservation and post-treatment pregnancies in young women affected by early breast cancerLuca Arecco, Roberto Borea, Isotta Martha Magaton, et al.
JAMA Network Open|December 11, 2025
Economic Evaluation of Comprehensive Genomic Profiling in an Advanced Solid Cancer PopulationLucas F van Schaik, Brigitte Maes, Pieter-Jan Volders, et al.
Nutrients|April 28, 2025
Impact of Dietary Supplements on Clinical Outcomes and Quality of Life in Patients with Breast Cancer: A Systematic ReviewLuca Scafuri, Carlo Buonerba, Oriana Strianese, et al.
Critical Reviews in Oncology/Hematology|May 30, 2024
Navigating the complexity of PI3K/AKT pathway in HER-2 negative breast cancer: biomarkers and beyondM Sirico, F Jacobs, C Molinelli, et al.
International Journal of Radiation Oncology, Biology, Physics|August 31, 2020
De-intensifying Radiation Therapy in HER-2 Positive Breast Cancer: To Boost or Not to Boost?Joseph Abi Jaoude, Majd Kayali, Evandro de Azambuja, et al.
Ecancermedicalscience|June 15, 2022
Timelines to initiate a phase III trial across the globe: a sub-analysis of the APHINITY trialMaria Alice Franzoi, Marion Procter, Chris Twelves, et al.
Pageof 26

Showing results (101-110 of 259) with videos related to

Sort By:
Pageof 26
Expert Opinion on Investigational Drugs|March 4, 2022
Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancerElisa Agostinetto, Agnese Losurdo, Guilherme Nader-Marta, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 16, 2017
Role of Troponins I and T and N-Terminal Prohormone of Brain Natriuretic Peptide in Monitoring Cardiac Safety of Patients With Early-Stage Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Receiving Trastuzumab: A Herceptin Adjuvant Study Cardiac Marker SubstudyDimitrios Zardavas, Thomas M Suter, Dirk J Van Veldhuisen, et al.
European Journal of Cancer (Oxford, England : 1990)|March 19, 2021
Cardiotoxicity of immune checkpoint inhibitors: A systematic review and meta-analysis of randomised clinical trialsElisa Agostinetto, Daniel Eiger, Matteo Lambertini, et al.
The Oncologist|June 15, 2022
Ovarian Function Suppression: A Deeper Consideration of the Role in Early Breast Cancer and its Potential Impact on Patient Outcomes: A Consensus Statement from an International Expert PanelBolivar Arboleda, Rupert Bartsch, Evandro de Azambuja, et al.
Expert Review of Anticancer Therapy|June 24, 2024
Current practices in oncofertility counseling: updated evidence on fertility preservation and post-treatment pregnancies in young women affected by early breast cancerLuca Arecco, Roberto Borea, Isotta Martha Magaton, et al.
JAMA Network Open|December 11, 2025
Economic Evaluation of Comprehensive Genomic Profiling in an Advanced Solid Cancer PopulationLucas F van Schaik, Brigitte Maes, Pieter-Jan Volders, et al.
Nutrients|April 28, 2025
Impact of Dietary Supplements on Clinical Outcomes and Quality of Life in Patients with Breast Cancer: A Systematic ReviewLuca Scafuri, Carlo Buonerba, Oriana Strianese, et al.
Critical Reviews in Oncology/Hematology|May 30, 2024
Navigating the complexity of PI3K/AKT pathway in HER-2 negative breast cancer: biomarkers and beyondM Sirico, F Jacobs, C Molinelli, et al.
International Journal of Radiation Oncology, Biology, Physics|August 31, 2020
De-intensifying Radiation Therapy in HER-2 Positive Breast Cancer: To Boost or Not to Boost?Joseph Abi Jaoude, Majd Kayali, Evandro de Azambuja, et al.
Ecancermedicalscience|June 15, 2022
Timelines to initiate a phase III trial across the globe: a sub-analysis of the APHINITY trialMaria Alice Franzoi, Marion Procter, Chris Twelves, et al.
Pageof 26